Hims & Hers Health stock opened at $49.10 on Friday. The business’s 50-day simple moving average is $35.05 and its two-hundred day simple moving average is $25.70. The company has a market cap ...

Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply. The company makes compounded versions of ...

The acquisition will strengthen the long-term durability of the company’s domestic supply chain, helping to ensure Americans can consistently access personalized medications Hims & ...

But when HIMS hit its last swing high on December 6 (using closing prices), the stock's closing price of $34.23 was "only" 47% above its 50-day moving average of $23.29. In a similar fashion ...

Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic supply chain and meet rising demand for personalized medications.

FDA's update led to renewed uncertainty for a growing group of telehealth companies such as Hims & Hers that have built businesses around offering cheaper copies of the branded medications.

Investing.com -- On Friday, shares of Hims&Hers Health Inc (NYSE:HIMS) dropped over 20% following an FDA announcement that the supply shortage of Novo Nordisk (NYSE:NVO)'s weight loss and diabetes ...

Hims & Hers acquired a California-based peptide facility to strengthen its supply chain, improve quality control, and expand personalized tr The FDA announced the semaglutide shortage was resolved ...

Hims & Hers Health Inc. has acquired a California ... the telehealth company has built a $14.5 billion business selling lower-cost, unbranded versions of popular medications like Viagra.

The acquisition closed in early February, and Hims & Hers expects to continue strengthening infrastructure capabilities as demand for personalized treatment continues to grow. For more information ...

The acquisition will strengthen the long-term durability of the company’s domestic supply chain, helping to ensure Americans can consistently access personalized medications Hims & Hers Health ...

Hims & Hers (NYSE:HIMS) has delivered blockbuster performance over the past month and was on its way to delivering over 200% returns. The surge was boosted after it announced its acquisition of ...